Skye Bioscience Inc (SKYE) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access SKYE Annual Balance Sheets →
Reviewing balance sheet figures over time helps illustrate how Skye Bioscience Inc manages its resources, obligations, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent8.15
Short-term Investments, Total8.96
Cash & Short-term Investments16.00
Other Current Assets0.23
Prepaid Expense, Current AS1.22
Total Current Assets18.57
Equipment/Property/Plant Net0.76
Other Assets, Noncurrent0.09
Total Assets19.42
Liabilities
Accounts Payable, Current AC3.94
Employee-related Liabilities, Current AC0.23
Loans Payable, Current NO0.25
Other Liabilities, Current5.98
Total Current Liabilities10.40
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
OperatingLeaseRightOfUseAsset0.06
Loss Contingency Accrual Carrying Value Current2.57
Operating Lease Liability Current0.06
Total Liabilities10.40
Stockholders' Equity
Common Stock Value0.04
Additional Paid In Capital Common Stock208.36
Retained Earnings / Accumulated Deficit-199.38
Other Equity0.00
Common Stockholder's Equity9.01
Total Stockholder's Equity9.01
Liabilities & Stockholder's Equity19.42
4 historic quarters locked

Sign in to unlock the full Skye Bioscience Inc balance sheet history.

About Skye Bioscience Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001628280-26-056968

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.